Predictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study
{{output}}
Objectives: Abrocitinib is approved for moderate-to-severe atopic dermatitis (AD); however, real-world data evaluating its efficacy in AD control using multidimensional-treatment-targets like optimal-disease-control (ODC) and mod... ...
